Fast forward to this year’s ASCO congress, and it seems TIGIT may be starting to bounce back. Roche has reported encouraging phase 1b/2 results with tiragolumab plus its PD-L1 inhibitor ...
Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer ... combination in the ARC-7 trial at this year’s ASCO congress. They are competing with the likes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback